The basics:

• Johnson & Johnson finalizes $1B acquisition of Firefly Bio
• Firelink platform targets hard-to-treat KRAS-driven cancer tumors
• Deal expands J&J’s oncology pipeline, targeted therapies
• J&J also announces new partnership with Sail Biomedicines

Johnson & Johnson has finalized its $1 billion acquisition of Firefly Bio Inc.

As part of the all-cash transaction that closed July 29, the New Brunswick-based healthcare giant gained access to a proprietary technology designed to target hard-to-treat cancer tumors.

At the heart of the deal is the biotech’s Firelink platform. The technology uses antibodies to deliver protein-degrading drugs directly into KRAS-driven cancer cells, according to J&J.

In addition to boosting its cancer drug pipeline, the move aims to expand the company’s work in targeted therapy for solid tumors.

J&J’s lineup spans a wide range of cancer treatments, such as multiple myeloma drugs Darzalex and Carvykti. It also includes newer therapies, such as Rybrevant, Talvey and Tecvayli.

M&A moves

Along with advancing R&D efforts in recent years, J&J has been bulking up its oncology offerings with M&A deals.

In December 2025, J&J finalized its $3.05 billion acquisition of clinical-stage biotech Halda Therapeutics OpCo. Inc. At the time, J&J said the buy would grow its presence in solid tumors and prostate cancer treatments.

Since its 2022 founding, San Francisco-headquartered Firefly has raised nearly $100 million in venture funding. Investors have included Eli Lilly, Versant Ventures and MPM BioImpact.

John Reed, J&J’s executive vice president of innovative medicine and research & development, says purchasing Firefly “marks an important step in advancing new approaches to better address difficult-to-treat solid tumors.”

“By bringing together Firefly Bio’s differentiated technology with our deep expertise in oncology and antibody engineering, we are well positioned to accelerate the development of more precise and effective therapies. We are excited to welcome the talented Firefly Bio team to Johnson & Johnson as we continue this work together,” he said.

[W]e are well positioned to accelerate the development of more precise and effective therapies.
– John Reed, executive vice president of innovative medicine and R&D, Johnson & Johnson

$785M deal in the works

The completion of the deal came on the same day J&J unveiled a strategic partnership with Sail Biomedicines. The plan focuses on developing next-generation autoimmune disease therapies.

Under the agreement, J&J will make an initial payment of $785 million, including a $465 million equity investment in Cambridge, Mass.-headquartered Sail. There could be additional payments of up to $140 million if Sail hits certain development milestones, the announcement said.

There’s also an option for J&J to acquire the biotech for $2.58 billion, the companies said.

According to J&J, the partnership will be centered on in-vivo CAR-T therapies, which are designed to reprogram immune cells directly inside a patient’s body instead of extracting them.

Reed said, “People living with serious immune-mediated diseases continue to need treatments that can deliver deeper, more durable disease control. Sail’s innovative platform represents an exciting new approach that seeks to harness the power of CAR-T therapy in a simpler, more scalable way.

“By working together with Sail, we aim to accelerate the development of innovative therapies that have the potential to fundamentally transform how immune-mediated diseases are treated,” he added.